Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy

Circulation. 2021 Jul 20;144(3):249-251. doi: 10.1161/CIRCULATIONAHA.121.054663. Epub 2021 Jul 19.

¹ TIMI Study Group, Division of Cardiovascular Medicine (N.A.M., K.O., M.T., R.P.G., M.S.S., D.A.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.O.).
³ Department of Pathology (P.J.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
⁴ National Heart and Lung Institute, Imperial College London, United Kingdom (P.S.S.).
⁵ Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.).
⁶ Amgen, Thousand Oaks, CA (A.L.P., H.W.).

No abstract available

Keywords: CV outcomes; PCSK9 inhibition; guidelines; stable ASCVD; troponin.

Publication types